AstraZeneca Group (AZN)
AstraZeneca Group Key Statistics
Pro Data ExportCurrent Valuation
| Market Cap | 53.28B |
| Enterprise Value | 56.52B |
| PE Ratio | 6.324 |
| PE 10 Pro | Go Pro |
| PEG Ratio | 0.4587 |
| Price / Sales Ratio | 1.632 |
| Price / Book Value | 2.453 |
| EV / Revenues Pro | Go Pro |
| EV / EBITDA Pro | Go Pro |
| EV / EBIT Pro | Go Pro |
| Operating Earnings Yield Pro | Go Pro |
Dividends and Shares
| Dividend | |
| Dividend Yield | 9.50% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | March 19, 2012 |
| Ex-Dividend Date | Feb. 15, 2012 |
| Last Split Factor | 3.00 |
| Last Split Date | April 8, 1998 |
Profitability
| Gross Profit Margin | 81.29% |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin | 22.32% |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 1.365 |
| Debt to Equity Ratio | 0.432 |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -5.33% |
| Year to Date Stock Returns | -10.93% |
| 1 Year Stock Returns | -20.59% |
| 3 Year Stock Returns | 1.15% |
| 52 Week High | 52.54 |
| 52 Week Low | 40.76 |
Income Statement
| Revenues TTM | 32.65B |
| Revenue Per Share TTM | 25.26 |
| Revenue Growth | -11.37% |
| Gross Profit TTM | 26.59B |
| EBITDA TTM Pro | Go Pro |
| Income from Cont. Ops Pro | Go Pro |
| Net Income TTM | 8.723B |
| Earnings Per Share TTM | 6.52 |
| Other Comprehensive Income Pro | Go Pro |
Cash Flow Statement
| Cash Investing TTM | -1.529B |
| Cash Financing TTM | -8.952B |
| Cash Operations TTM | 7.471B |
| Capital Expenditures |
Share Statistics
| Shares Outstanding | 1.292B |
Balance Sheet
| Cash and ST Investments | 6.332B |
| Total Assets | 50.76B |
| Liabilities | 29.04B |
| Book Value | 21.72B |
| Book Value per Share | 16.81 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 9.383B |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
You may also be interested in these AZN related companies
AZN News
$AZN stop at 40 on 1/3. Have owned a ton of it since early '10. Cost basis ~46 (not inc. divies)
about 4 days ago by WallStreetBean
about 4 days ago by WallStreetBean
RT @SeemaCnbc Cancer data expected to move big pharma $JNJ $PFE $AZN
about 10 days ago by StockTwits
about 10 days ago by StockTwits
$AZN “no longer operating in isolation as a pharmaceutical organization.” http://stks.co/3nwQ
about 14 days ago by WallStreetBean
about 14 days ago by WallStreetBean
AstraZeneca (AZN) Says SYMBICORT Shows Similar Safety Profile to Budesonide in Certain Asthma Patient Groups
May 10, 9:02AM Street Insider
May 10, 9:02AM Street Insider
UPDATE - Canaccord Genuity Downgraded Ardea Biosciences (RDEA) To 'Hold'; Q1 Is Non-Event In Light Of Acquisition By AZN
May 08, 9:14AM Street Insider
May 08, 9:14AM Street Insider
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 20 days ago by abubnic
about 20 days ago by abubnic
$AMRN U.K.'s second-biggest drugmaker, pharmaceutical giant $AZN, based in London is sniffing around Ireland's small biotech $AMRN
about 23 days ago by JasonMilano8
about 23 days ago by JasonMilano8
News related to $AZN, currently +0.3% since open: 'Impax Labs falls on weak sales, new FDA warning' http://stks.co/3bhx
about 26 days ago by TradeBot
about 26 days ago by TradeBot
what kinda drug is that? RT @JNapodano $AZN reported $16M in sales of Vimovo - not great, but still higher than consensus. $POZN.
about 27 days ago by WallStreetBean
about 27 days ago by WallStreetBean
Morning News: April 26, 2012 | via @EddyElfenbein http://stks.co/3Wht $FED $DB $NDX $AAPL $CAT $AZN
about 31 days ago by STNet
about 31 days ago by STNet
$AZN trouble in paradise: AstraZeneca CEO to step down as Q1 profit plunges http://stks.co/3WZ3 (holding)
about 31 days ago by WallStreetBean
about 31 days ago by WallStreetBean
News related to $AZN: 'AstraZeneca CEO to step down as Q1 profit plunges' http://stks.co/3WIC
about 32 days ago by TradeBot
about 32 days ago by TradeBot
@taketheplunge $AMRN $AZN has been linked to every biotech on the market in the last 3 months. $AZN could buy...
about 32 days ago by jackofalltrade
about 32 days ago by jackofalltrade
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 41.23 | +0.05 | +0.12% | 53.28B |
| AZK | 4.72 | +0.11 | +2.39% | 769.97M |
| AZC | 1.63 | +0.13 | +8.67% | 235.05M |
| AYR | 11.60 | +0.37 | +3.29% | 839.61M |
| BCRX | 3.26 | +0.00 | +0.00% | 150.09M |
| BCR | 99.90 | -0.09 | -0.09% | 8.473B |
| BCPC | 30.31 | -0.25 | -0.82% | 885.36M |
| BCOM | 4.20 | +0.01 | +0.24% | 125.54M |
| BCO | 23.23 | -0.32 | -1.36% | 1.089B |
| BCH | 84.05 | +0.83 | +1.00% | 12.18B |
